> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Clinical Hold on AZ Blood Cancer Drug
- URL: https://www.fdaweb.com/clinical-hold-on-az-blood-cancer-drug/
- Published: 2021-10-21T12:00:00.000Z
- Updated: 2026-09-14T17:19:48.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150417

FDA has placed a clinical hold on an AstraZeneca clinical trial of its investigational blood cancer drug AZD5991\. *Fierce Biotech* [reports](https://www.fiercebiotech.com/biotech/fda-slaps-clinical-hold-astrazeneca-cancer-drug-amid-heart-safety-scare-combo-test?ref=fdaweb.com) the company had already put a hold on the trial after heart issues were found in one patient being treated with the drug.

AZ told the online newsletter that an asymptomatic elevation in cardiovascular laboratory parameters occurred among the patient group receiving AZD5991 in combination with AbbVie/Roche’s venetoclax (Venclexta) FDA-approved blood cancer medicine. The cardiovascular issue was not seen in patients receiving AZD5991 as monotherapy, it said.

A company spokesperson told the newsletter the “asymptomatic elevation has since been resolved. We are now in the process of conducting a full analysis of the study data and working closely with FDA for the benefit of the patients.”